[1]
|
盛佳敏, 俞晓晴, 李晖, 范云. PD-1/PD-L1抑制剂治疗NSCLC脑转移的免疫机制与临床研究进展[J]. 中国肺癌杂志, 2020, 23(11): 976-982.
|
[2]
|
Li, W. and Yu, H. (2020) Separating or Combining Immune Checkpoint Inhibitors (ICIs) and Radiotherapy in the Treatment of NSCLC Brain Metastases. Journal of Cancer Research and Clinical Oncol-ogy, 146, 137-152.
https://doi.org/10.1007/s00432-019-03094-9
|
[3]
|
Li, J., Wang, M., Xu, S., et al. (2022) The Strategies and Mech-anisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Frontiers in Pharmacology, 13, Article ID: 841623. https://doi.org/10.3389/fphar.2022.841623
|
[4]
|
Eguren-Santamaria, I., Sanmamed, M.F., Goldberg, S.B., et al. (2020) PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 26, 4186-4197.
https://doi.org/10.1158/1078-0432.CCR-20-0798
|
[5]
|
Ohe, Y., Imamura, F., Nogami, N., et al. (2019) Osimertinib versus Standard-of-Care EGFR-TKI as First-Line Treatment for EGFRm Advanced NSCLC: FLAURA Japanese Subset. Japanese Journal of Clinical Oncology, 49, 29-36.
https://doi.org/10.1093/jjco/hyy179
|
[6]
|
Duruisseaux, M., Martínez-Cardús, A., Calleja-Cervantes, M.E., et al. (2018) Epigenetic Prediction of Response to Anti-PD-1 Treatment in Non-Small-Cell Lung Cancer: A Multicentre, Ret-rospective Analysis. The Lancet Respiratory Medicine, 6, 771-781. https://doi.org/10.1016/S2213-2600(18)30284-4
|
[7]
|
Goldberg, S.B., Schalper, K.A., Gettinger, S.N., et al. (2020) Pembrolizumab for Management of Patients with NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis from a Non-Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 21, 655-663. https://doi.org/10.1016/S1470-2045(20)30111-X
|
[8]
|
Mansfield, A.S., Aubry, M.C., Moser, J.C., et al. (2016) Temporal and Spatial Discordance of Programmed Cell Death-Ligand 1 Expression and Lymphocyte Tumor Infiltration between Paired Primary Lesions and Brain Metastases in Lung Cancer. Annals of Oncology, 27, 1953-1958. https://doi.org/10.1093/annonc/mdw289
|
[9]
|
Galea, I., Bechmann, I. and Perry, V.H. (2007) What Is Immune Privilege (Not)? Trends in Immunology, 28, 12-18.
https://doi.org/10.1016/j.it.2006.11.004
|
[10]
|
Berghoff, A.S. and Preusser, M. (2015) The Inflammatory Microen-vironment in Brain Metastases: Potential Treatment Target? Chinese Clinical Oncology, 4, 21.
|
[11]
|
Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy [Published Correction Appears in Immunity. 2014 Nov 20, 41(5): 866]. Immunity, 41, 49-61.
https://doi.org/10.1016/j.immuni.2014.06.010
|
[12]
|
Lorger, M. and Felding-Habermann, B. (2010) Capturing Changes in the Brain Microenvironment during Initial Steps of Breast Cancer Brain Metastasis. The American Journal of Pathology, 176, 2958-2971.
https://doi.org/10.2353/ajpath.2010.090838
|
[13]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[14]
|
Mansfield, A.S., Herbst, R.S., de Castro, G., et al. (2021) Outcomes with Pembrolizumab Monotherapy in Patients with Pro-grammed Death-Ligand 1-Positive NSCLC with Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clinical and Research Reports, 2, Article ID: 100205. https://doi.org/10.1016/j.jtocrr.2021.100205
|
[15]
|
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., et al. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo plus Pemetrexed and Platinum for Previously Un-treated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. https://doi.org/10.1200/JCO.19.03136
|
[16]
|
Abdulhaleem, M., Johnston, H., D’Agostino, R., et al. (2022) Local Control Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases. Journal of Neuro-Oncology, 157, 101-107. https://doi.org/10.1007/s11060-022-03951-7
|
[17]
|
LeCompte, M.C., Hughes, R.T., Farris, M., et al. (2020) Impact of Brain Metastasis Velocity on Neurologic Death for Brain Metastasis Patients Experiencing Distant Brain Failure after Initial Stereotactic Radiosurgery. Journal of Neuro-Oncology, 146, 285-292. https://doi.org/10.1007/s11060-019-03368-9
|
[18]
|
Sun, C., Zhou, F., Li, X., et al. (2020) PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases. OncoTargets and Therapy, 13, 12777-12786.
https://doi.org/10.2147/OTT.S286600
|
[19]
|
Taube, J.M., Klein, A., Brahmer, J.R., et al. (2014) Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clinical Cancer Research, 20, 5064-5074.
https://doi.org/10.1158/1078-0432.CCR-13-3271
|
[20]
|
Le, A., Mohammadi, H., Mohammed, T., et al. (2022) Local and Distant Brain Control in Melanoma and NSCLC Brain Metastases with Concurrent Radiosurgery and Immune Checkpoint Inhibition. Journal of Neuro-Oncology, 158, 481-488. https://doi.org/10.1007/s11060-022-04038-z
|
[21]
|
van Bussel, M.T.J., Beijnen, J.H. and Brandsma, D. (2019) In-tracranial Antitumor Responses of Nivolumab and Ipilimumab: A Pharmacodynamic and Pharmacokinetic Perspective, a Scoping Systematic Review. BMC Cancer, 19, 519.
https://doi.org/10.1186/s12885-019-5741-y
|